Uplevity is the trade name of a cosmetic ingredient whose correct identification requires specifying the specific version of the product. The original peptidic solution of Uplevity contains acetyl tetrapeptide-2, whereas Uplevity e-Lift contains tetrapeptide-1. These are two separate ingredients, not different names for the same substance. Research by the manufacturer and a limited number of published studies concerning these ingredients justify an analysis of their potential cosmetic effects. However, they do not confirm that every product containing Uplevity provides identical results. 1
This article focuses on the original Uplevity peptide solution. The e-Lift version is discussed solely to explain differences in the identity of the ingredients. The supplier’s studies, published experiments, and conclusions that would require stronger evidence regarding finished cosmetic products are presented separately.
What is Uplevity? Names, synonyms, and identity of the component
When evaluating claims regarding the efficacy of Uplevita, it is first necessary to prepare an accurate characterization of the component’s identity. This should distinguish between the trade name, the name according to the International Nomenclature of Cosmetic Ingredients (INCI), the solution supplied by the manufacturer, and the finished cosmetic product. These names refer to different levels of identification. It cannot be assumed that a product containing a small amount of the supplier’s solution contains the same amount of isolated peptide. The mere presence of a peptide does not also confirm that the product has been tested under the same conditions as the manufacturer’s demonstration formulation.
Historical documents may contain various trade descriptions, therefore the date of publication and the exact formulation designation are important. If the source only mentions the name „Uplevity”, it is justified to consider the identification incomplete until the INCI list or the manufacturer’s documentation is found. This avoids the erroneous attribution of the results of the Uplevity e-Lift research to the original ingredient. Differentiation is particularly important in SEO content, where closely related trade names may appear in the same search results.
The term „Uplevity peptide” is a useful search term, but it does not constitute a complete analytical identifier. The scientific description should indicate acetyl tetrapeptide-2 and specify whether the material under study was a commercial solution, a purified peptide preparation, or an ingredient in a ready-made formulation.
Uplevity is associated with the cosmetics ingredients offerings of Lubrizol and Lipotec. The trademark identifies the commercial material, while acetyl tetrapeptide-2 specifies its named peptide component. The consumer cream containing this material constitutes a third, distinct entity: a ready-to-use formulation with its own carrier, concentrations of ingredients, packaging, stability, and intended use. These three levels should remain separate when interpreting the studies.
A particularly useful identification source is the 2024 demonstrative formulation from Lubrizol, in which the original Uplevity and Uplevity e-Lift are listed separately. The former contains water, acetyl tetrapeptide-2 and caprylic glycol, while the latter contains water, tetrapeptide-1 and caprylic glycol. The document also includes a disclaimer that the proposed formulation has not been tested for efficacy, safety or effectiveness. This is a formulation document, not a clinical study. 1
Terms such as „lifting peptide” or „firming peptide” describe cosmetic positioning intended for specific purposes. They do not provide an amino acid sequence, analytical specifications, or evidence of a universal mechanism of action. Therefore, in scientific searches, the full trade name, INCI name, and the date of the document should be taken into account. Searching solely for the term „Uplevity” may overlook studies indexed under the name acetyl tetrapeptide-2. On the other hand, searching for the INCI name may lead to publications unrelated to facial skin tightening.
How is Uplevity classified? Peptide, protein, mixture, or other substance?
Tetrapeptide consists of four amino acid residues linked by peptide bonds. Acetylation is a covalent modification and forms part of the chemical identity indicated in the INCI name. However, the INCI name itself should not be used to reconstruct the full amino acid sequence, stereochemical configuration, purity, or molecular mass. These data require specific structural documentation or appropriately verified technical documentation.
The distinction between the active ingredient and the commercial mixture is not solely a matter of nomenclature. Water and caprylic glycol affect the physicochemical environment in which the peptide is delivered. The finished cream additionally contains emulsifiers, oils, preservatives, and other substances that can affect the product’s properties. The analytical identity of the peptide and the measured efficacy of the entire formulation therefore constitute two separate issues.
Cosmetic claims also differ from pharmacological classifications. A peptide used in skincare does not become a peptide drug because it appears in mechanistic studies. At the same time, the lack of therapeutic status does not preclude the scientific study of cosmetic parameters such as measured firmness or skin appearance. Any claim should remain consistent with the category and the evidence that supports it.
The peptide component of original Uplevity is a modified tetrapeptide, which is a short chain of four amino acid residues. The supplied solution is a mixture. It can therefore be properly described as a solution of the cosmetic ingredient containing a peptide, but not as a single, pure molecule.
The term „acetyl” indicates a chemical modification. It does not convert the four-residue peptide into a protein nor does it prove that the substance reaches a specific layer of the skin. Similarly, the terms „biomimetic,” „of natural origin,” and similar cosmetic descriptions do not independently confirm clinical efficacy. The classification answers the question of what the material is, whereas the efficacy study analyzes the action of a specific formulation under defined conditions.
The proper area of evidence evaluation is the study of cosmetic formulations. Medical claims regarding the treatment of diseases, the regeneration of deep tissues, or the achievement of an effect equivalent to surgical lifting would require a different and much stronger evidence base. Neither the short peptide chain nor the presence of a component in a cosmetic catalog confirms such results.
The structure and composition of Uplevity – what has been established?
When comparing the supplier’s documentation with the list of ingredients, percentages should be interpreted taking into account the amount to which they refer. The percentage given may indicate the mass fraction of the commercial solution in the formulation, the concentration of a specific peptide in that solution, or the laboratory concentration used in the cellular test. These values cannot be used interchangeably without knowledge of the composition and the basis of the calculations.
This is also important for stability and analytical studies. The result obtained for the purified peptide in an aqueous test medium may not describe its behavior in an emulsion containing numerous interacting components. Similarly, the composition of the solution supplied does not confirm the concentration of the peptide retained in the finished product after processing or storage. These issues require appropriate measurements in the actual formulation.
Technical documentation is most valuable when it distinguishes between disclosed information and proprietary or unverified data. If the exact sequence or concentration of a peptide is not available in the cited material, this gap should be clearly indicated. A precise but unconfirmed molecular formula would be less useful than an accurate description of the available evidence.
The manufacturer's verified formulation identifies the named ingredients of the original solution, but does not disclose the complete batch specifications or specify the concentration of the pure peptide in all commercial versions. In particular, the cream described as containing 2% Uplevity solutions should not be presented as a product containing 2% pure acetyl tetrapeptide-2. Percentages refer to different materials. 1
This review does not assign a full amino acid sequence, summary pattern, or exact molecular weight to the commercial solution based on vendor descriptions. This information should come from reliable identification documentation or the technical specifications of the specific peptide. The presence of water and excipients also makes assigning a single molecular weight to the entire mixture incorrect.
For the reproducibility of the studies, a description should include the INCI name, the supplier’s material, the batch number, the content of the peptide, if disclosed, the vehicle and the concentration in the finished product. When comparing publications, the exposure should be presented on the same basis. A cell experiment using a specific mass concentration of the peptide cannot be automatically compared with a cream containing a percentage of the diluted commercial solution.
Studies on Uplevity – evidence in humans, animals and in the laboratory
Research by a manufacturer involving people
The number of groups and the observation periods provided by the supplier must be kept exactly, because they determine the scale of the evidence. The nineteen participants in one assessment and the forty in the other provide preliminary information, but the small number limits the ability to assess rare reactions and variability between age groups and skin types. The observation periods of 55 and 56 days determine the duration of the observation. They do not show that any change persists after discontinuing the use of the product.
Instrumental firmness measurements can be sensitive to temperature, humidity, the location of the probe, and the way the skin is prepared by the participants before the assessment. Standardization and a reliable control group help distinguish the effect of the component from natural variability. A split-face study, which compares two sides of the face, can control some of the differences between the participants because both sides belong to the same person. However, differences in application, assignment of sides, and blinding of the evaluators can still influence interpretation.
Reports should also specify whether the results represent a change from the baseline value in one group, or a difference between the active formulation and the appropriately selected control. A favorable percent change from the baseline value does not automatically imply an additional effect of acetyl tetrapeptide-2. If uncertainty ranges, full protocols, or previously defined endpoints are not available, the appropriate determination is observation reported by the supplier rather than the final estimate of the comparative efficacy.
The Lubrizol presentation describes small cosmetic studies, including the evaluation of 19 women aged 50–60 for 55 days, a split-face microscopic comparison, and a separate evaluation of 40 women for 56 days. Changes in instrumentally measured firmness, features of the normal skin appearance, and facial appearance were reported. These are results reported by the supplier for specific formulations, not an independently repeated program of therapeutic studies. 2
The interpretation depends on the design of each assessment. Measurement before and after the application of the product is susceptible to the influence of time and the moisturizing effect of the carrier. Comparison with a correspondingly well-matched control formulation provides more information about the additional effect of the component, but still requires appropriate blinding, assignment to groups, prior determination of endpoints, and transparent statistical analysis. The presence of a comparator in one experiment should not be assumed for all experiments presented in the presentation.
Published cell studies
Atomic force microscopy enables the measurement of mechanical properties at the cellular level, whereas fluorescence microscopy allows the imaging of selected cellular structures. These methods provide valuable experimental observations, but none of them reproduces the multilayer structure of intact facial skin. The survival of keratinocytes may also depend on the culture medium, growth surface, cell density, and experimental exposure. The differences measured under such conditions cannot be directly converted into a percentage improvement in facial skin firmness in humans.
Including acetyl hexapeptide-50 in the 2018 publication constitutes another significant problem in attributing results. Each studied peptide must be linked to the appropriate measurements for it. The result obtained for one compound cannot be transferred to another simply because both are cosmetic peptides analyzed in the same publication. The study is important for developing mechanistic hypotheses, but it does not replace a controlled study of the finished product.
A 2018 study analyzed acetyl tetrapeptide-2 and acetyl hexapeptide-50 in frozen HaCaT keratinocytes using atomic force microscopy and fluorescence microscopy. Acetyl tetrapeptide-2 affected the measured stiffness of the cells under the conditions used. This is a laboratory result regarding the component, not evidence of facial lifting in humans. The results regarding the second peptide must remain attributed to it alone. 3
Cell stiffness and skin firmness are different parameters measured at different biological levels. An isolated cell does not possess the full skin barrier, connective tissue architecture, moisture gradients, or mechanical loads characteristic of living skin. Experiments of this type can serve as a basis for a mechanistic hypothesis, but they do not provide the missing data on exposure and clinical outcomes.
Human studies regarding another formulation and another indication
A hair study involving 100 participants shows how easily evidence can be exaggerated when the name of a component is extracted from a multi-ingredient formulation. Creatine, B vitamins, a peptide, and the accompanying shampoo formulation were the elements of comparison. If the study does not include groups that allow the impact of each component to be isolated, the observed difference should be attributed to the entire intervention being studied, and not solely to acetyl tetrapeptide-2.
The endpoint is also important. Acute telogen hair loss refers to hair loss, not to the contour of the face or the mechanical properties of the skin. Even a well-conducted study on hair does not answer the question of whether a face cream changes the firmness of the cheeks. It can be cited as evidence of the presence of a peptide in published studies involving humans, provided that the information about the different indication and limitations of attributing effects is maintained.
In a randomized, open-label study involving 100 women with severe telogen hair loss, a lotion containing creatine, acetyl tetrapeptide-2, and B vitamins was evaluated in combination with shampoo, compared to shampoo alone. Some results indicated a benefit of the multi-ingredient formulation. However, the study did not separate the effect of the peptide itself or evaluate Uplevity as a component of facial skin tightening. 4
This example shows why the consistency of the ingredient name is only the beginning of the evaluation of the publication. The population, the application site, the formulation, the control group, and the endpoint must also correspond to the claimed claim. A study on hair loss does not replace a study on a face cream.
Evidence from animal studies
Animal studies, if identified during the future update of the literature, will also require careful evaluation. The species, route of administration, dose, tissue and endpoint determine whether the result is relevant for the cosmetic formulation. An experiment demonstrating a change in protein expression in animal tissue does not confirm the apparent lifting effect in humans. The lack of animal studies in this selected review should not be presented as evidence of a comprehensive search that ended in a negative result.
In this study, no animal experiment was used as direct confirmation of the consumer claim about Uplevity’s firming effect. This is information about selected evidence, not a confirmation that such studies do not exist. More importantly, adding the results of an animal study would not resolve the fundamental question: whether a specific finished cosmetic product provides a significant and repeatable effect in target users.
Action mechanisms studied regarding Uplevity
The extracellular matrix biology is complex. Fibulin-5 is involved in the organization of elastic fibers; oxydase-like proteins are associated with the processes of cross-linking in the matrix, and collagen and elastin constitute important structural components. These functions explain why such markers can be analyzed in cosmetic studies. However, they do not confirm that the formulation applied locally repairs the intact network of elastic fibers or changes the mechanical architecture of the human skin.
Gene expression is one of the levels of evidence. A change in the amount of RNA information does not guarantee an appropriate change in the amount of protein, its activity, localization, or long-term tissue organization. Protein measurements provide additional information, but they also require interpretation in an experimental context. The formation of a mature extracellular network involves many stages and interactions that cannot be inferred from a single marker.
Delivery of the component to the skin constitutes a separate research problem. Peptides may encounter limitations related to formulation instability, interactions with other components, and the barrier properties of the outer layers of the skin. The evidence required for penetration depends on the proposed endpoint. The claim regarding the appearance of the skin surface may not require the same tissue exposure as the claim that the peptide acts directly on deeper-lying matrix-building cells. Researchers should indicate the proposed tissue compartment of interest, rather than assume penetration based on a laboratory mechanism.
The most informative mechanistic studies would combine chemical stability, exposure at the appropriate site, interaction with the biological target, and repeatable results in a controlled comparison of finished products. Until these compounds are demonstrated, the mechanism remains a hypothesis consistent with the selected observations rather than a complete causal explanation.
The mechanism proposed by the manufacturer includes the organization of extracellular matrix and cellular adhesion. The laboratory documentation describes experiments involving fibulin-5, a protein similar to lysosomal oxidase 1, elastin, collagen, and the expression of adhesion-related genes. These observations relate to experimental systems and should be presented as a proposed explanation in cosmetic studies, rather than as evidence of human facial tissue reconstruction. 2
A complete causal argument would require several related findings: the component remains intact in the product, the effective amount reaches the appropriate biological range, the proposed target changes at that point, and this change improves an important endpoint. Evidence regarding one stage does not automatically confirm the next one.
For example, increased gene expression is not equivalent to the formation of a mature, properly organized extracellular structure. The index obtained using microscopy is not interchangeable with the measurement of newly formed collagen in a biopsy. The firmness measurement can be useful, but still subject to the influence of hydration and measurement conditions. The mechanistic reliability and the benefits resulting from the use of a ready-made product must therefore be evaluated separately.
Limitations of scientific evidence regarding Uplevity
A systematic evaluation should address three questions: does the specific peptide exhibit measurable activity in the model, does the formulation tested by the supplier change the cosmetic parameter, and does the independently produced consumer product replicate this effect? The available sources address these questions to varying degrees. Combining them into a single claim of proven lifting would conceal gaps between the types of evidence.
The selection of endpoints deserves attention. Photographs can be influenced by lighting, angle of exposure, facial expression, and image processing. Instrumental measurements can be more objective, but they still depend on calibration and standardized conditions. Participant satisfaction is a useful subjective endpoint, but it does not identify the underlying biological mechanism. A well-designed study can include several measurements, simultaneously determining in advance which of them forms the basis of the main conclusion.
The second limitation is the transparency of publications. Producer presentations can convey technical results, but omit elements expected in a full, peer-reviewed study report, including details of randomization, the recorded protocol, all previously defined endpoints, and uncertainty of the results at the participant level. The appropriate approach is not to reject every result from the provider. Evidence should be carefully described and documentation from the provider should not be presented as independent confirmation.
Cosmetic safety also depends on the entire finished formulation and its intended users. Evaluation of irritations and allergies, preservative systems, packaging, and product stability are issues distinct from confirmation of efficacy. A small short-term study cannot establish safety in all skin conditions and life stages. Available evidence should be updated as new independent studies of finished products and well-characterized safety studies emerge.
The most important limitation is the discrepancy between the broad marketing language and the narrow research conditions. Provider’s studies can be useful, but independent replication of the results, full protocols, estimates of the effect along with uncertainty, and longer follow-up would facilitate the assessment of the evidence. The published study component provides context, not confirming the effectiveness of each brand formulation.
A targeted search in PubMed yielded two records based on the acetyl tetrapeptide-2 terminology. One relates to keratinocytes, and the other to a multi-component hair lotion. The database’s automatic translation of the query did not recognize the trade name Uplevity, therefore these results should not be presented as a complete number of studies on Uplevity. The original search result was preserved in the research files.
The safety interpretation also depends on the formulation. A brief cosmetic assessment cannot determine the frequency of rare events, pregnancy safety, or compliance with all other skincare products. Statements such as „no problems have been reported” and „no risk exists” have different meanings. At the same time, the limited evidence base alone does not prove that a component is ineffective or harmful. It only indicates the extent of the remaining uncertainty.
A convincing future study should compare formulations that differ only in the evaluated component, specify the intended users and the application site, previously define the main endpoint, standardize the measurement conditions, and report adverse events and participant withdrawals. Longer observation after the end of product use would help distinguish transient changes in appearance from permanent effects.
Most frequently asked questions about Uplevity
1. Does Uplevity mean one defined substance?
Not at every level of identification. The original Uplevity is a commercial solution containing a specific peptide component, while the broader brand also includes the e-Lift version. Therefore, before attributing a study to a specific claim, it is necessary to specify the exact product version and the component specification. The trade name alone is not sufficient. 1 In the scientific documentation, the exact product version and the INCI declaration must be recorded before searching for efficacy studies. This prevents the results regarding e-Lift, the original Uplevity, and consumer creams being combined under one trade name.
2. What do the available studies on Uplevity confirm?
They provide preliminary cosmetic and mechanistic evidence, with significant limitations regarding attribution of effects. The provider’s studies pertain to selected formulations, whereas identified scientific publications analyze the mechanism of action of cells and a multi-ingredient hair lotion. Collectively, they justify further research but do not confirm a universal facial lifting effect or therapeutic action. 2 3 4 Evidence is most valuable when each result is attributed to a precise research design. The manufacturer's observations in humans, measurements of cell mechanics, and the study of a multi-ingredient hair product constitute separate sources of evidence. None of these alone confirms the repeatable effect in all facial creams.
3. Is Uplevity e-Lift the same component as the original Uplevity?
No. The manufacturer provides different INCI names for the peptide ingredients for both materials. The result regarding one ingredient should not be attributed to the other without direct evidence, even if their names and cosmetic positioning are similar. Comparisons must take into account the exact product version. 1 The original ingredient and e-Lift contain different named peptides, although the supplier uses related trade names. A scientific comparison should verify the exact formulation card, the publication date, and the identity of the ingredient.
4. Is Uplevity a protein?
No. Its named active ingredient is a tetrapeptide, whereas the commercial solution is a mixture. Calling it a protein obscures the information about the short peptide chain and does not facilitate the interpretation of the evidence. The very classification of the chain length does not also determine the effectiveness of the finished cream. Peptides and proteins contain amino acid residues, but a four-residue cosmetic peptide is usually not considered a protein. The supplied mixture also contains non-peptide components, therefore distinguishing the molecule and the product is essential.
5. Does Uplevity Declaration 2% mean 2% pure peptide?
Not necessarily. The percentage of the delivered solution includes both its carrier and the peptide component. Without a verified specification of the active substance content, calculating this value as a percentage of pure peptide would be unreasonable. Comparisons should be based on the concentration provided by the manufacturer. To properly interpret such a percentage, it is necessary to know the concentration of the peptide in the supplier's solution and the amount of the solution added to the finished product. Without both values, it is not possible to calculate the exact concentration of pure peptide.
6. Does the result regarding the stiffness of the cells prove an improvement in the firmness of the facial skin?
No. The published experiment with keratinocytes measured the mechanical properties of the cells under laboratory conditions. The firmness of the entire skin also depends on the tissue architecture, hydration, and exposure. Therefore, the result supports the research hypothesis, but it does not replace the research of a finished product in humans. 3 The primary limitation is the scale of the experiment. The isolated keratinocyte does not replicate the extracellular matrix or the moisturizing conditions of intact facial skin. Direct claims regarding appearance require measurements in people using a specific ready-made formulation.
7. Does Uplevity need to penetrate the epidermis to confirm any cosmetic effect?
No. There is no one requirement for permeation that is appropriate for all cosmetic endpoints. The claim regarding skin appearance and the claim of direct remodeling of the underlying skin require different evidence. However, if the proposed mechanism involves action in the underlying skin, confirmation of delivery of the component to that layer becomes part of the argument, rather than a premise. The permeation requirements result from the type of claim. Demonstrating a visible surface effect differs from confirming direct activity in the underlying skin, which would require evidence of appropriate tissue exposure and interaction with a biological target.
8. Can the cream improve the appearance of the skin without confirming the formation of new collagen?
Yes. Changes in surface hydration, texture, or optical properties can improve the appearance of the skin. Confirmation of the production of new collagen in living human tissue requires appropriate biological measurement. The mere appearance of the photos does not allow us to determine this mechanism, even if the visual improvement is real. Appearance can change through several mechanisms related to formulation, including hydration and optical effects. Observations of these should not be called collagen synthesis without appropriate biological measurements directly confirming such mechanism.
9. Are the manufacturer’s studies worthless because they were funded by him?
No. Funding does not automatically invalidate the results, but it makes transparent methods, complete reporting, and independent replication of studies particularly valuable. The proper approach is to evaluate control groups and select endpoints, rather than blindly accepting a marketing summary or rejecting an experiment solely because of funding. A provider’s study can provide information if it is properly controlled and described clearly. Independent replication is important because it verifies that the results hold outside the original research environment.
10. Does the split-face type of study allow the activity of a peptide to be isolated?
This can be helped if the formulations differ only in the active ingredient being studied, and the allocation and evaluation are appropriate. If several ingredients differ, the comparison identifies the effect of the entire formulation, not the specific effect of the peptide. Therefore, before attributing causality, it is necessary to review the study design. Comparing both sides of the face with a properly selected control limits some of the variability between individuals, but does not eliminate differences in application or measurements. The formulations must be sufficiently similar to determine the additional effect of the active ingredient being studied.
11. Does the study of the hair lotion confirm the claims regarding the firming of the face by Uplevity?
No. The identified hair study used several ingredients in a different population and in a different application context. It does not allow for the isolation of acetyl tetrapeptide-2 activity or confirmation of facial lifting. The common name of the ingredient makes the publication relevant during a literature review, but it does not automatically mean that it supports the claimed claim. 4 The hair study also included another biological endpoint and a multi-component intervention. The results do not indicate the magnitude of the effect of the peptide itself or the facial cosmetic product.
12. Does the term „lifting” mean an effect equivalent to the procedure?
Such equivalence cannot be inferred from the word itself. A cosmetic claim of lifting should be based on a truly measured result, such as contour parameters or mechanical properties. Equivalence with the procedure would require a properly designed direct comparison, rather than similar advertising nomenclature. Claims that mimic the effects of medical procedures require their own direct comparative evidence. Without such studies, lifting should be interpreted solely in terms of specific reported cosmetic measurements.
13. Does the list of ingredients reveal the effective dose of the peptide?
It usually does not provide sufficient information to reproduce the exposure. The name confirms the declared presence of the ingredient, but does not specify the delivery, stability, or amount reaching the appropriate site. Therefore, confirmation of efficacy requires studies of the finished product, rather than calculations based solely on the position of the peptide in the list of ingredients. Ingredient lists generally do not disclose the active substance content, bioavailability, or amount remaining intact during storage. The name on the label cannot therefore replace a properly controlled study of the product’s activity.
14. Do short-term studies show that the results persist after the use has ended?
Only when they cover a sufficiently long period of observation after use. Measurements performed during the use of the product do not confirm the durability of the effect after discontinuation. Claims of long-lasting structural changes require observation designed to distinguish durability from the transient effects of the formulation. The persistence of the effect after discontinuation constitutes a separate endpoint that must be measured after discontinuation of the product. A study ending during the application period cannot distinguish permanent tissue change from a reversible cosmetic effect.
15. Does a more complex peptide formulation have to be more effective?
No. A higher number of ingredients increases the number of potential factors influencing the outcome, but does not confirm greater effectiveness. Comparisons must take into account complete formulations and appropriate endpoints. The number of peptides is neither a measure of exposure nor a substitute for a controlled study of the product's activity. Combining several peptides can make it more difficult, rather than easier, to attribute effects. Comparative studies should evaluate the complete formulation and control the influence of the vehicle and other active ingredients.
16. Do the studies on Uplevity confirm safety for all skin types?
No. Tolerance depends on the entire formulation and the population being studied. Evidence from a small, selected group does not allow for the exclusion of irritations or rare reactions in other users. Therefore, a broad claim of safety requires broader studies, not extrapolation based on the name of the peptide. The question of safety concerns the formulation, exposure, and population being studied. Small studies may detect frequent short-term irritations, but do not allow for a reliable assessment of rare adverse events or establish universal tolerance.
17. What would most strengthen the evidence regarding Uplevity?
Independent, well-controlled clinical trials of clearly defined finished products would be particularly useful. They should report significant magnitudes of effects, adverse events, and durability of results, with endpoints selected before the study began. Such work would reduce uncertainty regarding attribution of effects and their actual significance more effectively than additional, unverified marketing claims. Independently conducted, pre-registered comparisons of appropriately selected formulations with clear endpoints and complete reporting would provide the greatest improvement. They would also help determine whether the observed differences are meaningful to consumers.
Quality of studies – how to interpret claims regarding cosmetic peptides?
The practical assessment of evidence begins with identifying the source. First, it is necessary to determine whether the source is the original Uplevity, Uplevity e-Lift, isolated acetyl tetrapeptide-2, or a finished cosmetic containing several ingredients. Then it is necessary to identify the experimental system: cell culture, a cosmetic study sponsored by the supplier or an independently published study involving humans. Finally, it is necessary to record the actual endpoint and determine whether the comparator allows the effect of the peptide to be distinguished. These controls prevent the transformation of promising mechanistic observations into an unconfirmed consumer claim.
The language of the result description should correspond to the measurement used. The statement „the cellular mechanics parameter changed during cultivation” is narrower than „the skin became firmer.” Similarly, „the supplier reported a difference in instrumental assessment” is more precise than „independent studies proved a lifting effect.” Detailed descriptions do not diminish the value of the studies. They allow readers to understand what the evidence confirms and what cannot be determined based on it.
Statistical significance and practical importance are also distinct. A small, repeatable difference can be detected by a sensitive instrument without causing a noticeable visual change. In contrast, subjective improvement may be significant for the consumer, although it is difficult to attribute it to a single component. Well-designed studies should report the magnitude of effects, variability, adverse events, and whether participants or evaluators were blinded to the assignment to groups.
Research priorities and unresolved questions
One of the priorities is transparent reporting on the composition of the solution of the ingredient and its stability in representative finished products. This information would make it easier to compare the concentrations of the laboratory exposure with the percentages used in cosmetic formulations. The next priority is to determine whether a specific peptide reaches the biological range proposed in the mechanism of action under realistic conditions of product use.
Independent, controlled studies involving humans should distinguish between original Uplevity and e-Lift and separate the effects of acetyl tetrapeptide-2 from the effects of the remaining components of the formulation. The studies should use appropriate vehicle controls, define the characteristics of the participants, previously defined primary endpoints, and consistent imaging and mechanical measurements. As far as possible, they should assess both the short-term appearance of the skin and the durability of the effects after cessation of use.
Larger studies of tolerance would help determine how results vary depending on skin type, sensitivity, and the type of formulation. Until these questions are resolved, the most reasonable description is to designate acetyl tetrapeptide-2 as a cosmetic research ingredient for which preliminary mechanistic evidence and human study results reported by the supplier are available, rather than as a substance with a defined, universal facial lifting effect.
Educational, medical and regulatory reservations
The article is of a purely scientific and educational nature. It does not constitute medical advice, does not serve to diagnose or treat diseases, does not recommend an individual care regimen and does not confirm the safety or effectiveness of any specific commercial product. The identity of the cosmetic ingredient, analytical quality, tolerance and the effect of the finished formulation constitute separate issues.
The results reported by the supplier and laboratory experiments should not be considered evidence of medical efficacy, deep tissue regeneration, or equivalence to clinical procedures. Requirements for cosmetic claims depend on the relevant regulations and evidence relating to the finished product. For individual health or skin problems, appropriate qualified specialists should be consulted.
Conclusions
The original Uplevity can best be described as a cosmetic solution containing acetyl tetrapeptide-2. Its identity should be distinguished from the e-Lift version, and evidence regarding this component is limited to results from unrelated multi-ingredient products. Available studies justify cautious, formulation-dependent discussion of its cosmetic potential. However, they do not confirm its universal lifting, tissue regeneration, or therapeutic effects.
References
- Lubrizol Advanced Materials, Inc. (2024, April 2). Lift Up_Me complete care gel cream for face: M-0078(EU) [Demonstration formulation]. https://www.lubrizol.com/-/media/Lubrizol/Personal-Care/Documents/Formulations/Facial-Care/M0078EU.pdf
- The Lubrizol Corporation. (2015). Uplevity: Counteracting the force of gravity (Version 4) [Manufacturer research presentation]. https://www.smarterskincare.co.uk/wp-content/uploads/2023/03/P-Uplevity-2.pdf
- Kobiela, T., Milner-Krawczyk, M., Pasikowska-Piwko, M., Bobecka-Wesołowska, K., Eris, I., Święszkowski, W., & Dulinska-Molak, I. (2018). The effect of anti-aging peptides on mechanical and biological properties of HaCaT keratinocytes. International Journal of Peptide Research and Therapeutics, 24(4), 577–587. https://doi.org/10.1007/s10989-017-9648-7
- Turlier, V., Darde, M. S., Loustau, J., & Mengeaud, V. (2021). Assessment of the effects of a hair lotion in women with acute telogen effluvium: a randomized controlled study. Journal of the European Academy of Dermatology and Venereology, 35(Suppl. 2), 12–20. https://doi.org/10.1111/jdv.17245